STOCK TITAN

DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Welcome to our dedicated page for DEFENCE THERAPEUTICS A news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on DEFENCE THERAPEUTICS A stock.

Defence Therapeutics Inc. (symbol: DTCFF) is a Canadian biopharmaceutical company specializing in immune-oncology therapeutics and drug delivery technologies. The company recently announced the successful development of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an anti-PD-1 immune-checkpoint inhibitor. Defence's unique approach involves the use of reprogrammed mesenchymal stromal cells and AccuTOX® to induce potent antigen presentation for enhanced immune response. The ARM-002TM vaccine is highly versatile and adaptable, being tested on

Rhea-AI Summary

Defence Therapeutics has completed the first tranche of its non-brokered private placement, raising $775,000 through the sale of units at $0.50 each. Each unit comprises one common share and half a warrant, with each whole warrant exercisable at $1.00 per share within 24 months. The company paid $14,000 in finder's fees and issued 28,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital. All securities are subject to a four-month hold period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) announces corporate updates and financing plans. Key points include:

1. Sebastien Plouffe returns as CEO, replacing Kwin Grauer.

2. New board appointments: Dr. Philippe Lefrançois and Mr. Arnab De.

3. Dr. Moutih Rafei steps down from the board but remains CSO.

4. Joseph Meagher leaves the board but stays as CFO during transition to Arnab De.

5. 200,000 stock options granted to new directors at $0.60 per share.

6. Non-brokered private placement announced for up to $3 million at $0.50 per unit, with each unit including one common share and half a warrant.

7. Proceeds to be used for advancing preclinical and clinical programs, and working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has announced a leadership change as it transitions from preclinical to clinical stage. Kwin Grauer has been appointed as the interim Chief Executive Officer, replacing Sébastien Plouffe. Grauer, who joined the company's Board of Directors in December 2022, brings over 20 years of experience in operating, buying, and selling small and medium-sized businesses.

Grauer is a CPA, CA with expertise in financing, financial modeling, and corporate restructuring. He has served on the Board of Langara College, including roles as Chair of the Finance and Audit Committee and Board Chair. Plouffe will continue to serve as a director of Defence Therapeutics, with the company acknowledging his contributions to its growth and development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary

Defence Therapeutics Inc. (DTCFF) is exploring the potential of its Accum® technology to enhance the efficacy of GLP-1 agonists in treating obesity and type 2 diabetes. The company aims to develop a formulation that improves the in vivo stability, distribution, tolerability, and activity of GLP-1 analogs.

This initiative addresses the growing global obesity crisis, with over 4 billion people expected to be overweight or obese by 2035. Current GLP-1 analogs face challenges such as gastrointestinal side effects, injection management, and patient compliance. Defence's Accum® technology could potentially overcome these limitations by acting as a protective nanocarrier.

The GLP-1 receptor agonist market is projected to reach US$125 billion by 2033, highlighting the significant opportunity in this therapeutic area.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) has announced an update on its collaboration with Orano Support SAS to develop a novel Radio-Immuno-Conjugate (RIC) for cancer treatment. The project aims to create a next-generation RIC using Auger electron (AE) emitter elements combined with Defence's Accum® technology.

The Accum® technology addresses key limitations of RICs, such as endosomal sequestration and poor nuclear accumulation. Defence has developed various Accum® variants with different properties and has secured their production. The company has also patented the ability of some Accum® variants to deliver antibodies or antibody-conjugates into the nucleus.

Defence has arranged for in vitro and in vivo preclinical studies to be conducted by the radiopharmaceuticals team at the Canadian Nuclear Laboratories. This collaboration aims to open a new cancer therapy market based on promising radiotherapeutics using AE emitter radionuclides.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) has been approved for the Canadian Nuclear Research Initiative Health (CNRI-H) Program by Canadian Nuclear Laboratories (CNL). This collaboration aims to accelerate Defence's radio-immuno-conjugates project, focusing on novel 111In-AccuTOX®-Trastuzumab constructs.

The project's objectives include:

  • Synthesizing and evaluating constructs to demonstrate AccuTOX®'s role in evading endosome entrapment
  • Ensuring nuclear localization for 111In to emit Auger Electrons
  • Developing constructs lethal to HER2-positive cancer cells
  • Identifying a potent 111In-AccuTOX®-Trastuzumab molecule for treating solid tumors resistant to current HER2-targeting therapies

The global radiopharmaceuticals market is projected to reach $21.8 billion by 2033, with a CAGR of 10.6% from 2024 to 2033.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Defence Therapeutics has received a No Objection Letter (NOL) from Health Canada for its Phase I clinical trial of ACCUM-002 (AccuTOX) for treating unresectable Stage IIIB and IV melanoma. The trial, designated ACCUM-002-01, will assess the safety and tolerability of intratumoral administration of AccuTOX, both as a monotherapy and combined with the LAG-3 checkpoint inhibitor relatlimab and PD-1 inhibitor nivolumab (Opdualag). Secondary objectives include collecting preliminary efficacy data and determining the Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D). The trial is expected to be conducted in hospitals in Quebec and Ontario. According to Vision Research Reports, the global cancer immunotherapy market is projected to grow significantly, reaching USD 280.11 billion by 2033, with a CAGR of 8.34% from 2024 to 2033.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Defence Therapeutics (CSE: DTC, OTCQB: DTCFF) has announced that its Accum-002™ (AccuTOX®) exhibits dual functionality: acting as a tumor-killing molecule and an immune booster. AccuTOX® works synergistically with Immune Checkpoint Inhibitors (ICI) to enhance the immune system's capability to recognize and attack tumors. This is particularly significant as many solid tumors create a 'cold' environment that impedes immune response, leading to low success rates in ICI treatments. AccuTOX® transforms these cold tumors into 'hot' tumors, significantly increasing the effectiveness of ICIs. Preclinical studies showed a tenfold increase in efficacy when AccuTOX® is combined with various ICIs. Defence is open to partnerships to further develop this promising treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.58%
Tags
none
-
Rhea-AI Summary

Defence Therapeutics has announced that its second-generation ARM-X anti-cancer vaccine, in combination with an anti-PD-1 immune-checkpoint inhibitor, has successfully inhibited the growth of pre-established ovarian cancer in animal models. The study demonstrated complete responses in nearly all treated animals, extending their survival beyond 80 days post-vaccination. This development highlights the versatility of Defence's ARM-X platform, which previously showed effectiveness against solid T-cell lymphoma, melanoma, and pancreatic cancer. The ARM-X vaccine requires lower antigen amounts, making it adaptable to patients' needs regardless of cancer type. The company is also testing ARM-X for colon cancer to set targets for upcoming Phase I-IIa trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Defence Therapeutics' Chief Scientific Officer, Dr. Moutih Rafei, discussed the company's Accum platform for cancer treatments on Money Talk Radio with Ellis Martin. The interview highlighted Defence's innovative approach in the field of immune-oncology, focusing on the enhancement of vaccine efficacy and drug delivery systems. The Accum platform aims to improve the targeting and effectiveness of cancer treatments, potentially transforming the landscape of oncology therapies. The discussion emphasized the platform's potential to make significant advances in cancer treatment.

Listeners can access the full interview on Money Talk Radio's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of DEFENCE THERAPEUTICS A (DTCFF)?

The current stock price of DEFENCE THERAPEUTICS A (DTCFF) is $0.41 as of September 23, 2024.

What is the market cap of DEFENCE THERAPEUTICS A (DTCFF)?

The market cap of DEFENCE THERAPEUTICS A (DTCFF) is approximately 20.1M.

DEFENCE THERAPEUTICS A

OTC:DTCFF

DTCFF Rankings

DTCFF Stock Data

20.10M
43.03M
4.74%
Biotechnology
Healthcare
Link
United States of America
Vancouver